Mirum Pharmaceuticals
Presence
Mirum Pharmaceuticals is one of the...
Mirum Pharmaceuticals is a company listed under the stock ticker MIRM (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Mirum Pharmaceuticals
- Chris Peetz, Director, President and Chief Executive Officer
- Mike Grey, Executive Chairman of the Board
- William Fairey, Director
Popular executive movements at Mirum Pharmaceuticals
- Joanne Quan has joined the company as Chief Medical Officer (posted on January 17 2024).
- Eric Bjerkholt has joined the company as Chief Financial Officer (posted on September 12 2023).
Create your alert
to follow the executive moves at Mirum Pharmaceuticals.
Pharmaceuticals
Mirum Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Mirum Pharmaceuticals
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- View more press releases Close
Social media about Mirum Pharmaceuticals
- Mirum Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Mirum Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Chris Peetz 
Call Mirum Pharmaceuticals at +1 650...
